

Textbook of Interventional Cardiovascular Pharmacology

Nicholas N. Kipshidze MD PhD

FACC FESC FSCAI

Professor of Medicine and Surgery

Consultant Cardiologist

Cardiovascular Research Foundation

Director of Research

Lenox Hill Heart and Vascular Institute

New York NY USA

Director and Physician in Chief

Central University Hospital

Tbilisi Georgia

Jawed Fareed PhD FACB

Professor of Pathology and

Pharmacology

Director of Hemostasis and

Thrombosis Research Laboratories

and Department of Pathology

Loyola University, Stritch School

of Medicine

Maywood IL USA

Jeffrey W. Moses MD FACC

Professor of Medicine

Director, Center for Interventional

Vascular Therapy

Director, Cardiac Catheterization

Laboratories

Columbia University Medical Center

New York-Presbyterian Hospital

New York NY USA

Patrick W. Serruys MD PhD

FACC FESC

Professor and Head

Interventional Department

Thoraxcenter

Erasmus University Medical Center

Rotterdam

The Netherlands

Associate Editor:

Cathy Kennedy MLS

Columbia University Medical Center

New York NY

USA

Forewords by Valentin Fuster MD PhD and Richard H. Kennedy PhD

Contents

List of contributors	ix
Foreword Valentin Fuster	xvii
Foreword Richard H. Kennedy	xix
Preface	xxi
Acknowledgments	xxiii
Color plates	xxv–xxxii
Part I Systemic and Endoluminal Therapy	
1 An overview of hemostasis and thrombosis Walter Jeske, Debra A. Hoppensteadt, Asad Shaikh, Jeanine M. Walenga, Mamdouh Bakhos, and Jawed Fareed	1
2 Principles of antiplatelet therapy Raul Altman, Alejandra Scazziota, and María de Lourdes Herrera	31
3 Glycoprotein IIb/IIIa inhibitors Sanjay Kaul	41
4 Adenosine diphosphate receptor inhibitors Michel E. Bertrand	59
5 Phosphodiesterase inhibitors: dipyridamole and cilostazol James J. Ferguson	69
6 Heparin, low molecular weight heparin Raphaelle Dumaine and Gilles Montalescot	79
7 Direct thrombin inhibition in percutaneous coronary intervention Derek P. Chew, Sam J. Lehman, and Harvey D. White	85
8 Clinical application of direct antithrombin inhibitors in acute coronary syndrome Shunji Suzuki, Hikari Watanabe, Takefumi Matsuo, and Masanori Osakabe	93
9 Oral antithrombin drugs Brigitte Kaiser	109
10 Rationale for direct factor Xa inhibitors in acute coronary syndromes Volker Laux and Markus Hinder	119
11 Combined anticoagulant and antiplatelet therapy Harry L. Messmore, Erwin Coyne, Meghan Businaro, Omer Iqbal, William Wehrmacher, and Walter Jeske	127
12 Fibrinolytic therapy Freek W. A. Verheugt	135

13	Resistance to antiplatelet drugs Paul A. Gurbel and Udaya S. Tantry	139
14	Lipid-lowering agents Andrew M. Tonkin and Omar Farouque	155
15	Improving the diagnosis and management of high blood pressure in the cardiac patient Clarence E. Grim	171
16	Homocysteine regulators Torfi F. Jonasson and Hans Ohlin	177
17	Role of systemic antirestenotic drugs and results of current clinical trials Ron Waksman	185
18	Role of systemic antineoplastic drugs in the treatment of restenosis after percutaneous stent implantation Alfredo E. Rodriguez	195
19	Antioxidants Umberto Cornelli	211
20	Iron chelation: deferoxamine and beyond Valeri S. Chekanov	241
Part II Local Therapy		
21	Stent-mediated local drug delivery Yanming Huang, Lan Wang, and Ivan De Scheerder	249
22	The application of controlled drug delivery principles to the development of drug-eluting stents Kalpana R. Kamath, Kathleen M. Miller, and James J. Barry	267
23	Brachytherapy Ravi K. Ramana, Ferdinand Leya, and Bruce E. Lewis	279
24	Polymers and drug-eluting stents Robert Falotico and Jonathon Zhao	289
25	Utilization of antiproliferative and antimigratory compounds for the prevention of restenosis Kalpana R. Kamath and James J. Barry	299
26	Anti-inflammatory drugs, sirolimus, and inhibition of target of rapamycin and its effect on vascular diseases Steven J. Adelman	315
27	Anti-migratory drugs and mechanisms of action Ivan De Scheerder, Xiaoshun Liu, and Yanming Huang	325
28	Antiangiogenetic drugs—mechanisms of action Christodoulos Stefanadis and Konstantinos Toutouzas	339
29	Vasculoprotective approach for restenosis Nicholas N. Kipshidze, Jean-François Tanguay, Alexandre C. Abizaid, and Antonio Colombo	347

30	Vascular endothelial growth factor Neil Swanson and Anthony Gershlick	355
31	Gene therapy: role in myocardial protection Alok S. Pachori, Luis G. Melo, and Victor J. Dzau	363
32	Antisense approach Patrick Iversen and Martin B. Leon	371
33	Principles of photodynamic treatment Thomas L. Wenger and Nicholas H. G. Yeo	381
Part III Cell Therapy and Therapeutic Angiogenesis		
34	Angiogenesis and myogenesis Shaker A. Mousa	393
35	Growth factor therapy Munir Boodhwani, Joanna J. Wykrzykowska, and Roger J. Laham	407
36	Cell transplantation for cardiovascular repair Doris A. Taylor, Harald Ott, and Patrick W. Serruys	419
37	Clinical trials in cellular therapy Joanna J. Wykrzykowska, Munir Boodhwani, and Roger J. Laham	439
Part IV Adjunctive Pharmacotherapy		
38	The heart failure patient Basil S. Lewis and Mihai Gheorghiade	451
39	The acute coronary syndrome patient John F. Moran	465
40	Cardiovascular interventional pharmacology in the diabetic patient Mitchell D. Weinberg and George D. Dangas	473
41	Atrial fibrillation during catheterization Yves L. E. Van Belle, M. F. Scholten, and Luc J. Jordaens	483
42	Contrast-induced nephropathy after percutaneous coronary interventions Ioannis Iakovou	493
43	Erectile dysfunction Graham Jackson	503
44	Peripheral arterial disease Zoran Lasic and Michael R. Jaff	515
45	Pharmacotherapy peri-percutaneous coronary intervention Waqas Ullah, Rakesh Sharma, and Carlo Di Mario	525
46	Pharmacologic management of patients with CTO interventions David R. Holmes, Jr	537

47	Newer pharmacologic approaches targeting receptors and genes Omer M. Iqbal, Debra A. Hoppensteadt, and Jawed Fareed	543
Part V Noncoronary Interventions		
48	Carotid artery stenting Amir Halkin, Sriram S. Iyer, Gary S. Roubin, and Jiri Vitek	555
49	Anticoagulants in peripheral vascular interventions Rajesh M. Dave, Azim Shaikh, and Mubin Syed	569
50	Repair of AAAs Alexandra A. MacLean and Barry T. Katzen	583
51	Interventions for structural heart disease Ralph Hein, Neil Wilson, and Horst Sievert	593
52	Pharmacological use of ethanol for myocardial septal ablation George D. Dangas, Edwin Lee, and Jeffrey W. Moses	603
	Epilogue: Anticoagulant management of patients undergoing interventional procedures Jawed Fareed	613
	Appendix A	619
	Appendix B	623
	Index	627